Pipeline
Our therapeutics are designed to target conserved mammalian pathways involved in age-related decline, with a focus on targets involved in musculoskeletal, renal, neuronal, and cardiovascular diseases.
Novel SOTA models
Our algorithms are designed in-house and held under trade secret. They read across thirty million scientific articles alongside public and private omics data, and rank interventions against conserved mechanisms of mammalian aging. Earlier, less advanced versions of the software have been published open-source for the wider scientific community, in journals across the Cell and Nature families.
Data nobody else has
Any algorithmic advance requires data of matching quality. We generate our own: terabytes of omic data from cats young and old, healthy and diseased, alongside longitudinal clinical records from every animal enrolled in our studies. None of it was commercially available, and none of it had been published.
Clinical validation
PURR-001 achieved 23% muscle mass increase, with clean biochemistry and haematology at every timepoint. PURR-004 went from a fifteen-candidate cell screen to an approved clinical trial in four months (manuscript in preparation). Both hold US provisional patents; PURR-001 dossier is in preparation for marketing authorisation.